Archive · 18 Sep 2026
Anthropic Builds Biology Lab While Expanding AI Drug Ambitions
Anthropic is a company that makes artificial-intelligence systems.
It has quietly created a laboratory where people and machines can do real biology experiments.
The company hopes AI can help find medicines for diseases that are hard to treat.
It says some experiments happen in its own lab and others happen with outside partners.
Anthropic wants its Claude system to help operate laboratory equipment.
People will still supervise the work because biology and AI can create safety risks.
The company is not running human drug trials right now.
It has also warned that powerful AI could be dangerous, so it is trying to balance faster research with caution.
Anthropic has established a San Francisco Bay Area wet lab for physical biology experiments, according to company confirmation and people familiar with the matter.
The company says it is combining in-house laboratory work with external partnerships while keeping human oversight central to safety.
Anthropic aims to use artificial intelligence to accelerate treatments for rare and previously difficult-to-treat diseases, though its specific targets remain undisclosed.
The company has expanded its life-sciences efforts through Claude Science, the acquisition of Coefficient Bio, new hiring, and partnerships with major pharmaceutical companies.
Anthropic is not currently running clinical trials, while acknowledging that drug development is uncertain and can take years after molecule discovery.
- Who
- Anthropic, including its head of life sciences Eric Kauderer-Abrams, is leading the effort.
- What
- Anthropic has established a wet lab and is expanding AI-related life-sciences and drug-development work.
- When
- The lab was confirmed in a Reuters interview on Tuesday; the company’s broader drug-program plans were announced in June.
- Where
- The laboratory is in the San Francisco Bay Area.
- Why
- Anthropic says it wants to use powerful AI to accelerate life-sciences research and develop treatments for neglected or difficult-to-treat diseases while managing safety risks.
Expansion Case
Caution Case
AI and laboratory automation
Expansion Case
Anthropic says AI-directed automation could accelerate laboratory work and help advance medicines, with some experiments conducted more quickly in its own facilities.
Caution Case
The company says human oversight remains essential, and its work comes amid warnings that advanced AI could contribute to catastrophic or biological risks.
Anthropic’s role in drug development
Expansion Case
Anthropic wants to pursue preclinical work in areas traditional companies may find financially unattractive and hopes to address difficult-to-treat conditions.
Caution Case
A company spokesperson clarified that the lab is not specifically for drug discovery, while the precise diseases, progress, and eventual drug prospects remain unclear.
Competition and trust
Expansion Case
Anthropic says it is focusing on needs industry would not address and has established boundaries so it is not competing directly with companies that bring drugs to market.
Caution Case
People familiar with the effort said customers may worry Anthropic could learn from competing drug programs, despite the company’s claim that customer data is walled off.
- Laboratory type
- A wet lab for physical biology experiments
- Location
- San Francisco Bay Area
- Current clinical status
- Anthropic is not running clinical trials for now
- Research focus
- Rare and previously considered “undruggable” diseases
- Acquisition
- Anthropic confirmed its acquisition of Coefficient Bio; media reports put the reported price at about $400 million in stock
- Technology
- The company launched Claude Science and the Model Hardware Standard
- External customers
- Anthropic provides life-sciences tools and services to companies including Genentech, Bristol Myers Squibb, and Novo Nordisk